MAPT and Alzheimer disease: Currently, the clinical diagnosis of AD is based on the MMSE, Montreal Cognitive Assessment (MoCA) grading test combined with magnetic resonance imaging and lumbar puncture, and the detection of abnormal biomarkers (i.e., levels of Aβ and phosphorylated tau proteins) in the blood and CSF (Jack et al., 2018).